Table 1 Relationship between NEIL3 expression and clinicopathology in the TCGA LUAD cohort
From: NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma
Characteristics | n | NEIL3 | χ2 | P value | |
|---|---|---|---|---|---|
Low expression | High expression | ||||
Total | 293 | 147 | 146 | Â | Â |
Age | 0.206 | 0.65 | |||
 ≤ 60 | 98 | 51 (52.05) | 47 (47.95) |  |  |
 > 60 | 195 | 96 (49.24) | 99 (50.76) |  |  |
Gender | 2.13 | 0.144 | |||
 Male | 138 | 63 (45.65) | 75 (54.35) |  |  |
 Female | 155 | 84 (54.19) | 71 (45.81) |  |  |
TNM stage | 7.689 | 0.004* | |||
 I and II | 223 | 122 (54.70) | 101 (45.30) |  |  |
 III and IV | 70 | 25 (35.70) | 45 (64.30) |  |  |
Tumor stage | 7.201 | 0.027* | |||
 I | 88 | 54 (61.40) | 34 (38.60) |  |  |
 II | 169 | 80 (47.30) | 89 (52.70) |  |  |
 III and IV | 37 | 14 (37.80) | 23 (62.20) |  |  |
Metastasis stage | 2.809 | 0.094 | |||
 Negative | 274 | 141 (51.50) | 133 (48.50) |  |  |
 Positive | 19 | 6 (31.60) | 13 (68.40) |  |  |
Node stage | 2.259 | 0.133 | |||
 Negative | 187 | 100 (53.50) | 87 (46.50) |  |  |
 Positive | 106 | 47 (44.30) | 59 (55.70) |  |  |